CRSP Stock Price - Search News

CRISPR, Evercore and CRSP

CRISPR (CRSP) Upgraded to Outperform by Evercore, Price Target Raised to $99

CRISPR's upcoming trial data and increasing demand for Casgevy drive Evercore's bullish outlook and a higher price target

Seeking Alpha · 12h

CRISPR upped to outperform by Evercore on upcoming data

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

ETF Daily News · 19h

CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $56.00

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock.

Investing.com on MSN · 12h

CRISPR Therapeutics stock rises following analyst upgrade

CRISPR Therapeutics (NASDAQ: CRSP) stock climbed 7% after receiving an upgrade from Evercore ISI, shifting from an In Line rating to Outperform. The biotechnology company, known for its CRISPR/Cas9 gene-editing platform,

Business Insider · 14h

Crispr Therapeutics AG (CRSP) Gets a Sell from Morgan Stanley

In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Crispr Therapeutics AG (CRSP – Research Report), with

2don MSN

Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the ...

Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

20h

Needham & Company LLC Reaffirms “Buy” Rating for CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham ...

Nasdaq22d

CRSP March 7th Options Begin Trading

If an investor was to purchase shares of CRSP stock at the current price level of $43.24/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

CRISPR, Evercore and CRSP

Related topics